Alkermes plc.
Alkermes plc. (ALKS): 14 pipeline candidates · 12 upcoming catalysts · ~14 mo cash runway · 9 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
13.7 months
D/E 1.43 · 0% dilution
Lead: Approved
14 candidates
12 upcoming, next in ~75d
0 buys · 18 sells (180d)
A transparent, data-derived signal for Alkermes plc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$7.4B
Cash
$351.6M
Quarterly Burn
$165.7M
Runway
13.7 mo
Revenue
$392.9M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (14 candidates)
| Drug | Phase |
|---|---|
| Alixorexton (ALKS 2680) | Phase 2/Phase 3 |
| ALKS 2680 | Phase 3 |
| ARISTADA | Approved |
| ARISTADA INITIO | Approved |
| INVEGA HAFYERA / BYANNLI | Approved |
| INVEGA SUSTENNA / XEPLION | Approved |
| INVEGA TRINZA / TREVICTA | Approved |
| LUMRYZ | Approved |
| LYBALVI | Approved |
| Olanzapine | Phase 3 |
Showing 10 of 14 candidates. Sign up for full pipeline.
Upcoming Catalysts (12)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
387
Total value held
$6.24B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 28,314,410 | $1.00B |
| vanguard capital management llc | 14,854,794 | $525.3M |
| baker bros. advisors lp | 10,012,267 | $354.0M |
| vanguard portfolio management llc | 9,511,112 | $336.3M |
| state street corp | 9,465,286 | $334.7M |
| renaissance technologies llc | 6,160,428 | $217.8M |
| american century companies inc | 6,072,103 | $214.7M |
| dimensional fund advisors lp | 4,522,378 | $159.9M |
| commodore capital lp | 4,200,000 | $148.5M |
| geode capital management, llc | 4,182,267 | $147.9M |
Showing top 10 of 387 institutional holders of Alkermes plc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Alkermes plc.'s pipeline?
Alkermes plc. (ALKS) has 14 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Alkermes plc.'s lead drug candidate?
Alkermes plc.'s most advanced tracked candidate is Alixorexton (ALKS 2680) (Phase 2/Phase 3) for Narcolepsy Type 2; Narcolepsy Type 1; Idiopathic Hypersomnia.
What is Alkermes plc.'s next catalyst?
Alkermes plc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain " — expected September 1, 2026.
What is Alkermes plc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Alkermes plc. has approximately 13.7 months of cash runway.
What is Alkermes plc.'s market capitalization?
Alkermes plc.'s market capitalization is approximately $7.4B.
Get the full picture on Alkermes plc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.